research use only

Finerenone (BAY 94-8862) Mineralocorticoid Receptor antagonist

Name: Finerenone (BAY 94-8862)
Brand: Selleck Chemicals
SKU: S9702
Availability: InStock
Rating: 5 (3 reviews)

Cat.No.S9702

Finerenone (FIN, BAY 94-8862) is a highly selective and orally available nonsteroidal antagonist of mineralocorticoid receptor (MR) with IC50 of 18 nM. Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease.

Chemical Structure

Molecular Weight: 378.42

Jump to

Quality Control

Batch: Purity: 99.97%

99.97

Related Targets	Adrenergic Receptor Estrogen/progestogen Receptor GPR Androgen Receptor Glucocorticoid Receptor ACE RAAS Progesterone Receptor Opioid Receptor THR
Other Mineralocorticoid Receptor Inhibitors	Esaxerenone (CS-3150) Apararenone Canrenone

Solubility

In vitro
Batch:

DMSO : 76 mg/mL (200.83 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 10 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5% DMSO 1 30% PEG300 2 65%cmc-na Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	1.000mg/ml (2.64mM)	Taking the 1 mL working solution as an example, add 50 μL of 20 mg/ml clarified DMSO stock solution to 300 μL of PEG300, mix evenly to clarify it; add 650 μL of cmc-na to the above system, mix evenly to clarify. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.500mg/ml (1.32mM)	Taking the 1 mL working solution as an example, add 50 μL of 10 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	378.42	Formula	C₂₁H₂₂N₄O₃	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	1050477-31-0	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	FIN, BAY 94-8862			SMILES	CCOC1=NC=C(C)C2=C1C(C3=CC=C(C=C3OC)C#N)C(=C(C)N2)C(N)=O

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC₅₀/Ki	MR (Cell-free assay) 18 nM
In vitro	In vitro, Finererone dose-dependently reduces aldosterone-induced smooth muscle cell (SMC) proliferation and prevents aldosteroneinduced endothelial cell (EC) apoptosis. This compound significantly reduces apoptosis of ECs and simultaneously attenuates SMC proliferation, resulting in accelerated endothelial healing and reduced neointima formation of the injured vessels.
In vivo	Finerenone improves endothelial dysfunction through an enhancement in NO bioavailability and a decrease in superoxide anion levels due to an upregulation in SOD activity. This is associated with an increase in renal SOD activity and a reduction of albuminuria.
References	[1] https://pubmed.ncbi.nlm.nih.gov/30356804/ [2] https://pubmed.ncbi.nlm.nih.gov/28926607/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-06-29)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07192952	RECRUITING	Left Ventricular Systolic Dysfunction; Heart Failure (Pediatric)	Bayer	2026-06-01	PHASE3
NCT07270367	NOT_YET_RECRUITING	Heart Failure	Subodh Verma	2025-12	PHASE3
NCT07575672	NOT_YET_RECRUITING	HFpEF - Heart Failure With Preserved Ejection Fraction; TAVI(Transcatheter Aortic Valve Implantation); Finerenone	Second Affiliated Hospital, Zhejiang University, School of Medicine	2026-07-01	PHASE3
NCT07594145	NOT_YET_RECRUITING	Type 1 Diabetes; T1D Heart Failure; Cardio-renal Vascular Function and Failure; Diabetic Chronic Kidney Disease	Oregon Health and Science University	2026-11-01	PHASE2
NCT07188805	RECRUITING	Left Ventricular Systolic Dysfunction; Heart Failure (Pediatric)	Bayer	2025-11-19	PHASE3
NCT06082063	RECRUITING	Cardiovascular Diseases; Heart Failure; Type 1 Diabetes; Kidney Failure	Steno Diabetes Center Copenhagen	2024-07-01	PHASE3

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):